Evidence map›Paper›PMID 25710710›Full record

ReviewCurrent opinion in hematology2015

New insights into iron regulation and erythropoiesis.

Airie Kim, Elizabeta Nemeth

Open access · greenAbstract readReview
In one paragraph

Review in Current opinion in hematology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 84 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
84citing papers in PubMed, 2 pooled it
12.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

84 citing papers in PubMed, 2 syntheses or guidelines pooled it, 166 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. The Effect of Vitamin DInternational journal of environmental research and public health · 2020
    Trial
  4. Trial
  5. Trial
  6. Trial
  7. Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2019
    Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. The effects of intracellular iron availability on the outcome ofJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2023
    Article

24 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Airie KimDepartment of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
Elizabeta Nemeth
University of California, Los Angeles · US

Funding

Hepcidin therapy for iron overload and hematologic disordersR01DK090554 · NIDDK · WEILL MEDICAL COLL OF CORNELL UNIV · PI RIVELLA, STEFANO · 2010 to 2021
$5.2M
The role of erythroferrone in iron homeostasis and in iron-loading anemiasR01DK065029 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI GANZ, TOMAS · 2004 to 2017
$4.9M
The Hepcidin-Ferroportin Axis in Anemia of Inflammation: Mechanisms and TargetsR01DK082717 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NEMETH, ELIZABETA · 2008 to 2012
$1.6M
Acute Anemia of Inflammation: Mechanisms and Novel TherapiesK08HL127293 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KIM, AIRIE · 2015 to 2019
$824k
NHLBI NIH HHS K08 HL127293NIDDK NIH HHS DK090554NIDDK NIH HHS R01 DK065029NIDDK NIH HHS R01 DK082717NIDDK NIH HHS R01 DK090554
6 · The paper itself

Abstract

purpose of reviewIron homeostasis and erythropoiesis regulate each other to ensure optimal delivery of oxygen and iron to cells and tissues. Defining the mechanisms of this crosstalk is important for understanding the pathogenesis of common conditions associated with disordered iron metabolism and erythropoiesis. RECENT

findingsStress erythropoiesis causes suppression of hepcidin to increase iron availability for hemoglobin synthesis. The erythroid hormone erythroferrone (ERFE) was identified as the mediator of this process. ERFE and additional candidates (TWSG1 and GDF15) may also mediate hepcidin suppression in ineffective erythropoiesis. Several mechanisms by which iron regulates erythropoiesis were also recently identified. Iron deficiency suppresses erythropoietin production via the IRP1-HIF2α axis to prevent excessive iron usage by erythropoiesis during systemic iron restriction. Iron restriction also directly impairs erythroid maturation by inhibiting aconitase, and this can be reversed by the administration of the aconitase product isocitrate. Another novel target is GDF11, which is thought to autoinhibit erythroid maturation. GDF11 traps show promising pharmacologic activity in models of both ineffective erythropoiesis and iron-restricted anemia. SUMMARY: This review summarizes exciting advances in understanding the mechanisms of iron and erythropoietic regulation, and development of novel therapeutic tools for disorders resulting from dysregulation of iron metabolism or erythropoiesis.

Indexed as

ErythropoiesisHepcidinsHumansIronIron OverloadHepcidinsIron

Identifiers

PMID25710710
PMCPMC4509743
OpenAlexW1972140920

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.